Investor Presentaiton

Biotechnology Overview ~$8.8B TOTAL REVENUE 2022 Revenue By Mix Non- recurring Recurring cytiva PALL Life Sciences GLOBAL GROWTH DRIVERS Shift in medicine towards biologics By Geography HGM ROW W. EU . By End-Market Lab/ Medical . Growth in biologics R&D pipeline Resrch. NA All financial metrics reflect FY 2022 results from continuing operations; all pie chart percentages are % of 2022 revenues. Bioprocessing Increasing focus on genomic medicine High-growth market investments in bioprocessing Strong global brands with leading market positions 15 DANAHER

View entire presentation